SIA
LXRX icon

Stancorp Investment Advisers’s Lexicon Pharmaceuticals LXRX Stock Holding History

Stancorp Investment Advisers’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$7K Hold
1,036
– – ﹤0.01% 497
2014
Q4 		$7K Buy
+1,036
New +$8.35K ﹤0.01% 478

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Stancorp Investment Advisers's LXRX Position: Q1 2015 in Review

Stancorp Investment Advisers held its Lexicon Pharmaceuticals (LXRX) position steady in Q1 2015 at 1,036 shares worth $7K. The position accounts for ﹤0.01% of the portfolio, ranked #497.

Stancorp Investment Advisers first reported a position in LXRX in Q4 2014 and has held it in 2 quarters since. 119 funds tracked by Wall St. Rank hold LXRX as of Q1 2015.

  • Stancorp Investment Advisers held 1,036 shares of Lexicon Pharmaceuticals worth $7K as of Q1 2015.
  • Stancorp Investment Advisers left its Lexicon Pharmaceuticals share count unchanged in Q1 2015.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #497 holding.
  • Stancorp Investment Advisers first reported a position in Lexicon Pharmaceuticals in Q4 2014 and has held it in 2 quarters since.
  • 119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.